Valion Bio, Inc. (VBIO): Total Assets

Annual figures by period end, from SEC filings.

$31.61M
As of 2025-12-31
$32.47M
As of 2026-06-30
+75.2%
3-year compound annual growth
2021-12-31: $15.04M2022-12-31: $5.88M2023-12-31: $5.16M2024-12-31: $2.81M2025-12-31: $31.61M$31.61M
2021-12-31 Total Assets (USD) 2025-12-31
Period endedTotal AssetsChange YoYSource filing
2025-12-31$31.61Mn/m2026-03-30, Balance as of period end
2024-12-31$2.81M-45.6%2026-03-30, Balance as of period end
2023-12-31$5.16M-12.2%2025-03-21, Balance as of period end
2022-12-31$5.88M-60.9%2024-03-25, Balance as of period end
2021-12-31$15.04Mn/a2023-03-31, Balance as of period end

Total Assets at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal AssetsChange YoY
Valion Bio, Inc. (VBIO)2025-12-31$31.61Mn/m
Nuvectis Pharma, Inc. (NVCT)2025-12-31$31.71M+70.4%
Equillium, Inc. (EQ)2025-12-31$31.89M+24.5%
Tvardi Therapeutics, Inc. (TVRD)2025-12-31$32.07M-8.9%
China Pharma Holdings, Inc. (CPHI)2025-12-31$31.00M+108.2%
Dare Bioscience, Inc. (DARE)2025-12-31$32.47M+46.9%
PDS Biotechnology Corp (PDSB)2025-12-31$30.49M-32.8%
Yarrow Bioscience, Inc. (YARW)2025-12-31$30.16M-54.9%
Sunshine Biopharma Inc. (SBFM)2025-12-31$30.08M-1.6%

Compare VBIO, NVCT, EQ, TVRD side by side · Screen every company in Pharmaceutical Preparations ↗